Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice

Clinical and Experimental Pharmacology and Physiology

Volumn 43, Issue 2, 2016, Pages 203-212

  Ostadhadi, Sattar ^a,b   Haj Mirzaian, Arya ^a   Nikoui, Vahid ^a   Kordjazy, Nastaran ^a   Dehpour, Ahmad Reza ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cannabinoid CB1 receptor; Depression; Mice; Opioid receptor; Stress

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CORTICOSTERONE; FLUOXETINE; MORPHINE; NALTREXONE; OPIATE RECEPTOR; ANTIDEPRESSANT AGENT; CANNABINOID 1 RECEPTOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; FOOTSHOCK; FORCED SWIM TEST; IMMOBILITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PHYSICAL STRESS; TAIL SUSPENSION TEST; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; DEPRESSION; DRUG EFFECTS; IMMOBILIZATION; INVERSE AGONISM; METABOLISM; PHYSIOLOGICAL STRESS; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DRUG INVERSE AGONISM; HINDLIMB SUSPENSION; MALE; MICE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID; STRESS, PHYSIOLOGICAL; SWIMMING;

EID: 84955573691     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12518     Document Type: Article

References (64)

1. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 2006; 27: 73-100.
2. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008; 51: 1356-67.
3. Steiner MA, Marsicano G, Nestler EJ, Holsboer F, Lutz B, Wotjak CT. Antidepressant-like behavioural effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 2008; 33: 54-67.
4. Shearman L, Rosko K, Fleischer R et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav. Pharmacol. 2003; 14: 573-82.
5. Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 2005; 57: 261-7.
6. 1 receptor antagonists in major depressive disorders. Trends Pharmacol. Sci. 2005; 26: 609-17.
7. Massi P, Vaccani A, Romorini S, Parolaro D. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. J. Neuroimmunol. 2001; 117: 116-24.
8. Vigano D, Rubino T, Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol. Biochem. Behav 2005; 81: 360-8.
9. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47: 345-58.
10. Childers SR, Fleming L, Konkoy C et al. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in braina. Ann. N.Y. Acad. Sci. 1992; 654: 33-51.
11. Anisman H, Matheson K. Stress, depression, and anhedonia: Caveats concerning animal models. Neurosci. Biobehav. Rev. 2005; 29: 525-46.
12. Chaperon F, Thiebot M. Behavioural effects of cannabinoid agents in animals. Crit. Rev. Neurobiol. 1998; 13: 243-81.
13. Barna I, Zelena D, Arszovszki A, Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: In vivo and in vitro studies in CB1 receptor knockout mice. Life Sci. 2004; 75: 2959-70.
14. Witkin J, Tzavara E, Nomikos G. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav. Pharmacol. 2005; 16: 315-31.
15. Haj-Mirzaian A, Ostadhadi S, Kordjazy N, Dehpour AR, Ejtemaei Mehr S. Opioid/NMDA receptors blockade reverses the depressant-like behaviour of foot shock stress in the mouse forced swimming test. Eur. J. Pharmacol. 2014; 735: 26-31.
16. Hill MN, McLaughlin RJ, Morrish AC et al. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 2009; 34: 2733-45.
17. Guan X-t, Shao F, Xie X, Chen L, Wang W. Effects of aspirin on immobile behaviour and endocrine and immune changes in the forced swimming test: Comparison to fluoxetine and imipramine. Pharmacol. Biochem. Behav. 2014; 124: 361-6.
18. Liu J, Garza JC, Bronner J, Kim CS, Zhang W, Lu X-Y. Acute administration of leptin produces anxiolytic-like effects: A comparison with fluoxetine. Psychopharmacology 2010; 207: 535-45.
19. Egashira N, Matsuda T, Koushi E et al. Δ 9-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test: Involvement of cannabinoid CB 1 receptor and serotonergic system. Eur. J. Pharmacol. 2008; 589: 117-21.
20. Gatley SJ, Gifford AN, Volkow ND, Lan R, Makriyannis A. 123 I-labeled AM251: A radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB 1 receptors. Eur. J. Pharmacol. 1996; 307: 331-8.
21. Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB 1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur. Neuropsychopharmacol. 2005; 15: 593-9.
22. Jiang W, Zhang Y, Xiao L et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic-and antidepressant-like effects. J. Clin. Investig. 2005; 115: 3104-3116.
23. Tzavara ET, Davis RJ, Perry KW et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for therapeutic actions. Br. J. Pharmacol. 2003; 138: 544-53.
24. Tzavara ET, Wade M, Nomikos GG. Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: Site and mechanism of action. J. Neurosci. 2003; 23: 9374-84.
25. Tanda G, Carboni E, Frau R, Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: A trait of drugs with antidepressant potential? Psychopharmacology 1994; 115: 285-8.
26. 1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur. J. Pharmacol. 2001; 426: R3-4.
27. Elphick MR, Egertova M. The neurobiology and evolution of cannabinoid signalling. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2001; 356: 381-408.
28. Nakazi M, Bauer U, Nickel T, Kathmann M, Schlicker E. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000; 361: 19-24.
29. Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol. 2001; 85: 468-71.
30. Szabo B, Dörner L, Pfreundtner C, Nörenberg W, Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 1998; 85: 395-403.
31. Herkenham M, Brady L. D9-Tetrahydrocannabinol and the synthetic cannabinoid CP-55, 940 induce expression of c-Fos mRNA in stressresponsive nuclei of rat brain. In Soc Neurosci Abstr. 1994. Miami Beach, Florida; 1676.
32. Wenger T, Ledent C, Tramu G. The endogenous cannabinoid, anandamide, activates the hypothalamo-pituitary-adrenal axis in CB1 cannabinoid receptor knockout mice. Neuroendocrinology 2003; 78: 294-300.
33. Patel S, Hillard CJ. Cannabinoid-induced Fos expression within A10 dopaminergic neurons. Brain Res. 2003; 963: 15-25.
34. 2 function. Neuroscience 1999; 91: 607-20.
35. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J. Neurosci. 1991; 11: 563-83.
36. Van Bockstaele E, Colago E, Valentino R. Amygdaloid corticotropin-releasing factor targets locus coeruleus dendrites: Substrate for the co-ordination of emotional and cognitive limbs of the stress response. J. Neuroendocrinol. 1998; 10: 743-58.
37. Butler PD, Weiss JM, Stout JC, Nemeroff CB. Corticotropin-releasing factor produces fear-enhancing and behavioural activating effects following infusion into the locus coeruleus. J. Neurosci. 1990; 10: 176-83.
38. Weidenfeld J, Feldman S, Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 1994; 59: 110-12.
39. Martín-Calderón J, Muñoz R, Villanúa M et al. Characterization of the acute endocrine actions of HU-210, a potent synthetic cannabinoid in rats. Eur. J. Pharmacol. 1998; 344: 77-86.
40. 9-tetrahydrocannabinol in rats. Brain Res. 1999; 839: 173-9.
41. Hohmann AG, Suplita RL, Bolton NM et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005; 435: 1108-12.
42. Hillard CJ, Jarrahian A. Cellular accumulation of anandamide: Consensus and controversy. Br. J. Pharmacol. 2003; 140: 802-8.
43. Pickel V, Chan J, Kash T, Rodriguez J, MacKie K. Compartment-specific localization of cannabinoid 1 (CB1) and μ-opioid receptors in rat nucleus accumbens. Neuroscience 2004; 127: 101-12.
44. Hojo M, Sudo Y, Ando Y et al. MU-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: Electrophysiological and FRET assay analysis. J. Pharmacol. Sci. 2008; 108: 308-19.
45. Shapira M, Vogel Z, Sarne Y. Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors. Cell. Mol. Neurobiol. 2000; 20: 291-304.
46. Canals M, Milligan G. Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors. J. Biol. Chem. 2008; 283: 11424-34.
47. 1)-receptors in the development and maintenance of opioid tolerance. Neuroscience 2007; 146: 1275-88.
48. da Fonseca Pacheco D, Klein A, de Castro Perez A, da Fonseca Pacheco C, De Francischi J, Duarte I. The μ-opioid receptor agonist morphine, but not agonists at δ- or κ-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br. J. Pharmacol. 2008; 154: 1143-9.
49. Bushlin I, Rozenfeld R, Devi LA. Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr. Opin. Pharmacol. 2010; 10: 80-6.
50. Sadaghiani MS, Javadi-Paydar M, Gharedaghi MH, Fard YY, Dehpour AR. Antidepressant-like effect of pioglitazone in the forced swimming test in mice: The role of PPAR-gamma receptor and nitric oxide pathway. Behav. Brain Res. 2011; 224: 336-43.
51. Zomkowski AD, Santos AR, Rodrigues AL. Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci. Lett. 2005; 381: 279-83.
52. Dulawa SC, Holick KA, Gundersen B, Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004; 29: 1321-30.
53. Lewis JW, Cannon JT, Liebeskind JC. Opioid and nonopioid mechanisms of stress analgesia. Science 1980; 208: 623-5.
54. Madden J, Akil H, Patrick R, Barchas JD. Stress-induced parallel changes in central opioid levels and pain responsiveness in the rat. 1977; 265: 358-360.
55. Kaster MP, Ferreira PK, Santos AR, Rodrigues AL. Effects of potassium channel inhibitors in the forced swimming test: Possible involvement of L-arginine-nitric oxide-soluble guanylate cyclase pathway. Behav. Brain Res. 2005; 165: 204-9.
56. Amiri S, Haj-Mirzaian A, Rahimi-Balaei M et al. Co-occurrence of anxiety and depressive-like behaviours following adolescent social isolation in male mice; possible role of nitrergic system. Physiol. Behav. 2015; 145: 38-44.
57. Haj-Mirzaian A, Amiri S, Kordjazy N et al. Blockade of NMDA receptors reverses the depressant, but not anxiogenic effect of adolescence social isolation in mice. Eur. J. Pharmacol. 2015; 750: 160-6.
58. Porsolt RD, Le Pichon M, Jalfre M. Depression: A new animal model sensitive to antidepressant treatments. Nature 1977; 266: 730-2.
59. Haj-Mirzaian A, Kordjazy N, Haj-Mirzaian A et al. Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests. Psychopharmacology 2015; 322: 3551-3561.
60. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology 1985; 85: 367-70.
61. Kordjazy N, Haj-Mirzaian A, Amiri S et al. Elevated level of nitric oxide mediates the anti-depressant effect of rubidium chloride in mice. Eur. J. Pharmacol. 2015; 762: 411-418.
62. Veenema AH, Meijer OC, de Kloet ER, Koolhaas JM, Bohus BG. Differences in basal and stress-induced HPA regulation of wild house mice selected for high and low aggression. Horm. Behav. 2003; 43: 197-204.
63. Droste SK, de Groote L, Atkinson HC, Lightman SL, Reul JM, Linthorst AC. Corticosterone levels in the brain show a distinct ultradian rhythm but a delayed response to forced swim stress. Endocrinology 2008; 149: 3244-53.
64. Amiri S, Shirzadian A, Haj-Mirzaian A et al. Involvement of the nitrergic system in the proconvulsant effect of social isolation stress in male mice. Epilepsy Behav. 2014; 41: 158-63.